Learn about Ginkgo's latest tech for cell therapy R&D, including recent data from our CAR screening platform.
We can help you discover novel CAR-T therapeutics, including candidates that may be effective against solid tumors.
would definitely recommend
say more engaging than average
rate useful
Vice President
Mammalian Engineering
Ph.D ChemEng UC Berkeley
Senior Director
Mammalian Engineering
Ph.D BioE MIT
• $500 million in infrastructure
• 550+ scientists, automation engineers & data experts
• Largest user of synthetic DNA in the world (100k+ constructs per year)
• 10,000 unique CAR-T signaling combinations
• 700,000 functional CAR-T tests in one screening campaign
• 100,000,000 T-cell transductions
With Ginkgo's foundry, we generate massive libraries of unique CAR designs with different signaling domains.
These can then be screened in an assay that mimics a solid tumor environment.
We'll present head-to-head tests, highlighting improved performance compared to standard signaling domains.
Ginkgo's cell therapy capabilities extend beyond current CAR-T strategies, toward reprogramming any cell in any way.
Discover and optimize the next generation of cell therapies for the endpoints that matter to you.
Ginkgo Bioworks, 27 Drydock Ave, Boston, MA 02210